EvidentIQ and Feel Therapeutics Launch Strategic Partnership
Data linkage shows the importance of integrating data sets for better health outcomes
The data linkage approach combines rich, self-reported patient data collected through EvidentIQ’s Carenity platform with continuous, physiological data captured by Feel’s data monitoring device, and translates them into digital biomarkers. The combined datasets offer a complete patient picture and generate new evidence, bringing RWE to the next level. Throughout the process, EvidentIQ and Feel Therapeutics employ patient recruitment & onboarding, data monitoring and linkage capabilities, and data science expertise. They will also apply study design services such as protocol writing, questionnaire development (ePROs, ediaries), as well as IRB/EC submission and advisory board.
DCT has become the new gold standard to optimize clinical trials
Catalyzed by the COVID-19 pandemic and supported by recent changes to the regulatory framework, DCT (Decentralized Clinical Trials) adoption has risen steadily in recent years, with an expected growth of 28% in 2022 and a total of more than 1,300 clinical trials including a virtual component expected to commence this year. EvidentIQ and Feel Therapeutics offer an innovative hybrid or fully virtual clinical trial experience that include patient insight-driven DCT strategy definition, study design, patient recruitment, trial management software suite, study monitoring and biostatistics. The joint offering leverages Carenity’s patient platform to design a patient centric DCT and accelerate patient recruitment, with state-of-the art electronic data capture (EDC) and eClinical solutions (eConsent, eCOA…) employed throughout the trial. Decentralization is further enabled by Feel’s data monitoring device, which captures digital biomarkers and passively monitors patients, as well as its data science expertise and the use of its proprietary biomarker discovery and real world data platform.
With this best-in-class data linkage and DCT offering, EvidentIQ and Feel Therapeutics become a strategic partner for the life sciences industry to run innovative, patient-centric studies and generate powerful, high quality data from clinical trials.
About Feel Therapeutics
Feel Therapeutics (FKA Sentio Solutions) is a San Francisco based company which develops digital biomarkers and therapeutics to reinvent the way we diagnose, manage, and care for mental health by using continuous, objective and passive data collection. The company is backed by top VC firms and has kicked-off deployments with large Health & Life insurers in the USA and Germany.
EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end-to-end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs, with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio including patient recruitment, patient engagement media and RWE solutions, EvidentIQ significantly aids customers in optimizing HTA submissions, pricing and reimbursement needs. EvidentIQ has become a pillar of Real-World Evidence and data science pioneering in digitalization of clinical research and offering state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA).
EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and over 150 SMB customers in over 20 countries, including the US, Germany, France, the UK, Italy, Japan, and China.
EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com
Global Business Development – RWE
Telefon: +33(0)6 45 71 33 37
E-Mail: thomas.verjus@evidentiq.com
